August 2024

SHANGHAI, Aug. 27, 2024 /PRNewswire/ — JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) of China has appr

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: